ClinicalTrialStartPulse: Outside the US only, page 3 of 4
Records 201 to 350 of the 500 newest listed for this hub. Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
| Record | Phase | Conditions | Enrollment |
|---|---|---|---|
| Sun Yat-sen University | Phase 3 | Non-Clear Cell Renal Cell Carcinoma (nccRCC) | 108 |
| Beijing Ditan Hospital | Phase 3 | Neurosyphilis | 778 |
| McGill University Health Centre/Research Institute of the McGill University Health Centre | Phase 3 | Pneumocystis Jirovecii Pneumonia | 416 |
| National Institute of Unani Medicine, Bengaluru | Phase 2 | MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) | 128 |
| Sir Run Run Shaw Hospital | Phase 3 | Rectal Cancer | 210 |
| Tanta University | Phase 2 | Rheumatoid Arthritis (RA | 100 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 3 | Acute Ischemic Stroke | 826 |
| Menoufia University | Phase 2 | Post Operative Analgesia | 152 |
| GuangZhou Cellgenes Biotechnology Co., Ltd. | Phase 2 | Ischemic Stroke or High-risk TIA (ABCD² ≥ 4) | 87 |
| Al-Azhar University | Phase 2 | No Reflow Phenomenon; Reperfusion Injuries, Myocardial; Myocardial Infarction; STEMI - ST Elevation Myocardial Infarction; Coronary Artery Disease (CAD); PCI | 100 |
| All India Institute of Medical Sciences | Phase 3 | Acute Ischemic Stroke | 440 |
| University Hospital, Clermont-Ferrand | Phase 3 | Breast Cancer; Breast Surgery; Surgical Site Infection (SSI); Surgical Site Infection Prevention | 1600 |
| University of Alberta | Phase 2 | Low Back Pain | 713 |
| Debiopharm International SA | Phase 1 | Renal Impairment | 60 |
| Boston Scientific Corporation | Observational | Acute Pulmonary Embolism | 30 |
| AeroRx Therapeutics Inc. | Phase 2 | COPD; Chronic Obstructive Pulmonary Disease (COPD); Lung Disease Chronic; Lung Diseases, Obstructive | 64 |
| University Health Network, Toronto | Phase 2 | Glottic Carcinoma | 150 |
| Capital Medical University | Phase 3 | Influenza, Human | 570 |
| West China Hospital | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | 1088 |
| Tortugas Neuroscience, Inc. | Phase 1 | Healthy Volunteers | 10 |
| Medira GmbH | Not applicable (device, behavioral) | Symptomatic Tricuspid Regurgitation (TR) Graded as Severe or Greater | 10 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Invasive Breast Cancer | 200 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 3 | Metastatic Breast Cancer (MBC); HER2-Positive Breast Cancer; Hormone Receptor-Positive Breast Cancer | 226 |
| University of Mississippi Medical Center | Phase 2 | Viral Diseases | 250 |
| Tongji Hospital | Phase 2 | Cervical Intraepithelial Neoplasia Grade 3 | 260 |
| Merck Sharp & Dohme LLC | Phase 4 | Pulmonary Arterial Hypertension | 30 |
| Canadian Cancer Trials Group | Phase 2 | Non Small Cell Lung Cancer | 160 |
| German Cancer Research Center | Phase 2 | Astrocytoma, IDH-Mutant, Grade 3; Astrocytoma, IDH-Mutant, Grade 4 | 216 |
| Lumosa Therapeutics Co., Ltd. | Phase 2 | Acute Ischemic Stroke | 10 |
| Alliance for Clinical Trials in Oncology | Phase 3 | Multiple Myeloma (MM) | 920 |
| Edesa Biotech Inc. | Phase 2 | Non-Segmental Vitiligo (NSV) | 80 |
| University of Sao Paulo | Phase 2 | Suicidal Ideation; Suicidal Behavior | 106 |
| University of Malaya | Phase 2 | Type 2 Diabetes Mellitus (DM) | 360 |
| Croma-Pharma GmbH | Observational | Lateral Canthal Lines (LCL); Perioral Rhytids | 71 |
| AstraZeneca | Phase 1 | Healthy | 32 |
| Biosense Webster, Inc. | Not applicable (device, behavioral) | Atrial Fibrillation | 42 |
| NeoChord | Not applicable (device, behavioral) | Degenerative Mitral Regurgitation; Degenerative Mitral Regurgitation (MR) Due to Leaflet Prolapse | 15 |
| Hunan Kelun Pharmaceutical Co., Ltd. | Phase 1 | Healthy Participants | 20 |
| Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1 | Inflammatory Bowel Disease(IBD) | 88 |
| Royan Stem Cell Technology Company | Phase 1 | Acute Ischemic Stroke | 10 |
| PharmaResearch Co.,Ltd | Observational | Periorbital Hollowing; Skin Aging | 30 |
| PharmaResearch Co.,Ltd | Observational | Skin Aging; Horizontal Neck Lines | 30 |
| Mabwell (Shanghai) Bioscience Co., Ltd. | Phase 1 | AML; Multiple Myeloma; CMML | 122 |
| Janssen Research & Development, LLC | Phase 1 | Leukemia, Myeloid, Acute; Myelodysplastic Neoplasms | 85 |
| Janssen Research & Development, LLC | Phase 1 | Relapsed or Refractory Multiple Myeloma | 17 |
| Genmab | Phase 1 | Malignant Solid Tumor | 8 |
| Janssen Research & Development, LLC | Phase 1 | Lymphoma, Non-Hodgkin; Refractory B-Cell NHL; Relapsed B-cell NHL | 58 |
| Johnson & Johnson Private Limited | Phase 4 | Multiple Myeloma | 75 |
| ChM sp. z o.o. | Not applicable (device, behavioral) | Tendon Injuries | 86 |
| Pfizer | Observational | Metastatic Colorectal Cancer | 1 |
| Peijia Medical Technology (Suzhou) Co., Ltd. | Not applicable (device, behavioral) | Aortic Stenosis | 150 |
| AstraZeneca | Phase 1 | Healthy Participants | 60 |
| SunGlow Innovations LLC | Phase 1 | Solid Tumor; Neoplasms | 50 |
| Jemincare | Phase 1 | ADPKD (Autosomal Dominant Polycystic Kidney Disease); Renal Edema | 32 |
| HerAccess ApS | Not applicable (device, behavioral) | Vestibulodynia; Vulvodynia; Vulvar Vestibulitis | 35 |
| A.M.I. Agency for Medical Innovations GmbH | Not applicable (device, behavioral) | Fecal Incontinence | 43 |
| Pfizer | Observational | Non-Small Cell Lung Cancer ALK-positive | 50 |
| Pfizer | Phase 1 | Healthy | 26 |
| Tanta University | Phase 2 | SBP - Spontaneous Bacterial Peritonitis | 60 |
| Tanta University | Phase 2 | SBP - Spontaneous Bacterial Peritonitis | 60 |
| Neurelis, Inc. | Phase 1 | Cerebral Cavernous Malformation | 40 |
| ATEMs | Not applicable (device, behavioral) | Osteoarthritis; Osteoarthritis Knee Pain; Knee Arthritis | 117 |
| Immunis, Inc. | Phase 1 | Dyskinesia, Medication-induced; Dyskinesia, Drug-Induced | 15 |
| Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 | Pancreatic Cancer | 18 |
| Shanghai Qilu Pharmaceutical Research and Development Center LTD | Phase 1 | Systemic Lupus Erythematosus; Rheumatoid Arthritis (RA); Primary Sjögren's Syndrome (pSS); Systemic Sclerosis (SSc) | 76 |
| Bosch Quantum Sensing GmbH | Observational | Technical Feasibility and Performance of the Sensor System; Healthy Adult; Healthy Adult Participants | 12 |
| Sanofi | Observational | Atherosclerotic Cardiovascular Disease | 93000 |
| Ipsen | Observational | Primary Biliary Cholangitis (PBC) | 50 |
| Clinical Research Consultants, Inc. | Not applicable (device, behavioral) | Refractory Glaucoma | 65 |
| Astellas Pharma Inc | Phase 4 | Geographic Atrophy; Age-Related Macular Degeneration | 17 |
| University Health Network, Toronto | Phase 2 | Triple-Negative Breast Cancer (TNBC) | 60 |
| Sanofi | Observational | Atherosclerotic Cardiovascular Disease | 18000 |
| AstraZeneca | Observational | Hypophosphatasia (HPP) | 200 |
| Sanofi | Observational | Atherosclerotic Cardiovascular Disease | 180000 |
| Sinocelltech Ltd. | Phase 1 | Hepatitis B | 60 |
| BeOne Medicines | Phase 1 | Solid Tumors; Advanced Solid Tumors | 90 |
| North Immunology Inc. | Phase 1 | Atopic Dermatitis (AD) | 96 |
| Elixiron Immunotherapeutics Inc. | Phase 1 | Food Effect in Healthy Volunteers | 25 |
| Guizhou Sinorda Pharmaceutical Co., Ltd. | Phase 1 | Colorectal Neoplasms; Stomach Neoplasms; Solid Tumor Malignancies | 78 |
| GlaxoSmithKline | Phase 1 | Hepatitis B | 98 |
| BTL Industries Ltd. | Not applicable (device, behavioral) | Low Back Pain; Radicular Syndrome; Sacroiliac Joint Dysfunction; Shoulder Impingement Syndrome; Rotator Cuff Tendinopathy; Shoulder Osteoarthritis | 60 |
| Sanofi | Phase 4 | Atopic Dermatitis | 56 |
| Guangdong ProCapZoom Biosciences Co., Ltd. | Phase 1 | Keratitis; Autoimmunity; Dry Eye Disease (DED) | 20 |
| Shanghai YingLi Pharmaceutical Co. Ltd. | Phase 1 | Solid Tumors; Ovarian | 45 |
| Aymes International Limited | Not applicable (device, behavioral) | Disease Related Malnutrition | 20 |
| OBS Medical Ltd | Not applicable (device, behavioral) | Organ Donation After Circulatory Death; Organ Donation; Clinical Decision Support Tool | 10 |
| Accro Bioscience (Suzhou) Limited | Phase 1 | Acute Graft-versus-Host Disease | 4 |
| Cajal Therapeutics Inc. | Phase 1 | Chronic Kidney Disease; Anemia | 24 |
| Hamad Medical Corporation | Observational | Hematological Malignancy; Hematopoetic Stem Cell Transplantation; Bloodstream Infection | 1000 |
| Varian, a Siemens Healthineers Company | Observational | Liver Ablation; Liver Cancer; Liver Cancer (Primary and Metastatic) | 63 |
| Keymed Biosciences Co.Ltd | Phase 1 | Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) | 48 |
| Novo Nordisk A/S | Phase 4 | Cardiovascular Risk; Chronic Kidney Disease | 300 |
| AJU Pharm Co., Ltd. | Phase 1 | Hypertension | 60 |
| Odyssey Therapeutics, Inc. | Phase 1 | Health Volunteers | 8 |
| Nano-X Imaging | Not applicable (device, behavioral) | Fracture; Erosion | 100 |
| MED-EL Elektromedizinische Geräte GmbH | Observational | Hearing Loss, Binaural; Cochlear Implantation | 36 |
| Wecare Probiotics Co., Ltd. | Not applicable (device, behavioral) | Protein Utilization | 100 |
| Helixon Biotechnology (Suzhou) Co., Ltd | Phase 1 | Health Adults; Asthma | 40 |
| AJU Pharm Co., Ltd. | Phase 1 | Peripheral Arterial Disease | 40 |
| Ambulanzpartner Soziotechnologie APST GmbH | Observational | ALS (Amyotrophic Lateral Sclerosis); SMA - Spinal Muscular Atrophy; Spinal Cord Diseases; Central Nervous System Diseases; Nervous System Diseases; Motor Neuron Disease | 2000 |
| Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd. | Phase 1 | Safety Issues | 30 |
| Merck Sharp & Dohme LLC | Phase 4 | Hypertension, Pulmonary | 40 |
| Nuvascular Inc | Not applicable (device, behavioral) | Intracranial Arterial Aneurysm | 30 |
| Viatris Innovation GmbH | Phase 1 | Chronic Coronary Syndrome | 20 |
| RDC Clinical Pty Ltd | Phase 4 | Exercise | 36 |
| Swiss Cancer Institute | Phase 2 | B-cell Lymphoma | 92 |
| Shaanxi Giant Biotechnology Co., Ltd | Not applicable (device, behavioral) | Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines) | 192 |
| Sanofi | Observational | Multiple Sclerosis | 3000 |
| BlissBot, Inc | Not applicable (device, behavioral) | Autism Spectrum Disorder; Autism Spectrum Disorder (ASD; ASD | 80 |
| Axter Therapeutics (Beijing) Co., Ltd | Phase 1 | mCRPC | 105 |
| Comeback Mobility Inc | Not applicable (device, behavioral) | Tibial Plateau Fracture | 86 |
| Pneumagen Ltd, a subsidiary of NorthLinks Bio | Phase 1 | Healthy Volunteers | 44 |
| NovaResp Technologies Inc | Not applicable (device, behavioral) | Obstructive Sleep Apnea | 50 |
| MED-EL Elektromedizinische Geräte GmbH | Not applicable (device, behavioral) | Hearing Loss, Binaural; Cochlear Implantation | 22 |
| Pfizer | Phase 1 | Alzheimer Disease | 98 |
| AbbVie | Observational | Platinum-Resistant FRα-Positive Ovarian Cancer; Platinum-Resistant FRα-Positive Fallopian Tube Cancer; Platinum-Resistant FRα-Positive Peritoneal Cancer | 500 |
| Biogen | Observational | Muscular Atrophy, Spinal | 74 |
| ADARx Pharmaceuticals, Inc. | Phase 1 | Hypertension; Hypertension,Essential | 28 |
| BYHEALTH Co., LTD | Not applicable (device, behavioral) | Healthy Infants | 370 |
| HALEON | Not applicable (device, behavioral) | Dentin Sensitivity | 192 |
| Nuwacell Biotechnologies Co., Ltd. | Phase 1 | PARKINSON DISEASE (Disorder); Cell Therapy; Human Induced Pluripotent Stem Cells; Deep Brain Stimulation; Phase 1 Clinical Trial; Dopaminergic Progenitor Cells | 12 |
| Jeil Pharmaceutical Co., Ltd. | Observational | Erosive Gastroesophageal Reflux Disease | 3000 |
| Xiamen Amoytop Biotech Co., Ltd. | Not applicable (device, behavioral) | Idiopathic Short Stature | 300 |
| Cochlear | Not applicable (device, behavioral) | Sensorineural Hearing Loss; Tinnitus | 14 |
| BeOne Medicines | Phase 1 | Solid Tumor; Advanced Solid Tumor; Metastatic Solid Tumor | 96 |
| BeOne Medicines | Phase 1 | Healthy Volunteers | 12 |
| Lantheus Germany GmbH | Phase 1 | Cardiac Amyloidosis | 15 |
| Biogen | Phase 1 | Healthy Volunteer; Muscular Atrophy, Spinal | 62 |
| Fisher and Paykel Healthcare | Not applicable (device, behavioral) | Lower Limb Ischaemia | 40 |
| WAKEZ HEALTH TECH ECOSYSTEM SRL | Not applicable (device, behavioral) | Depression / Major Depressive Disorder; Depressed Mood | 208 |
| Galderma R&D | Observational | Midface Volume Deficit; Midface Contour Deficiency | 300 |
| Ono Pharmaceutical Co., Ltd. | Phase 1 | Colorectal Cancer | 40 |
| Beijing Suncadia Pharmaceuticals Co., Ltd | Phase 1 | Alzheimer's Disease | 50 |
| Bionime Corporation | Not applicable (device, behavioral) | Diabetes Mellitus, Type 1 Diabetes; Diabetes Mellitus, Type 2; Diabetes, Gestational | 104 |
| AstraZeneca | Observational | Neurofibromatosis Type 1 (NF1) | 800 |
| iBio, Inc. | Phase 1 | Obesity & Overweight | 32 |
| Bionime Corporation | Not applicable (device, behavioral) | Diabetes (DM) | 324 |
| ChinaNorm | Not applicable (device, behavioral) | Assessment of Soothing, Moisturizing and Skin Barrier Repair Efficacy of Facial Skincare Products in Healthy Women | 124 |
| Sinovac Biotech Co., Ltd | Observational | Hepatitis A | 106 |
| Sichuan Baili Pharmaceutical Co., Ltd. | Phase 3 | Urothelial Carcinoma | 515 |
| Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Phase 3 | Triple Negative Breast Cancer | 537 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 3 | Chronic Myeloid Leukemia | 408 |
| Leica Microsystems (Schweiz) AG | Observational | High-Grade Glioma (WHO III-IV); Cerebral Vascular Conditions Requiring Surgical Intervention; Conditions Requiring Plastic and Reconstructive Surgery | |
| Seoul National University Hospital | Not applicable (device, behavioral) | Hip Arthroplasty; Spinal Anesthesia; Remimazolam; Patient-controlled Sedation | 104 |
| Bagcilar Training and Research Hospital | Observational | Overactive Bladder (OAB) | 115 |
| Tokat Gaziosmanpasa University | Not applicable (device, behavioral) | Test Anxiety | 168 |
| University of Calgary | Phase 2 | Cancer; Colorectal Cancer | 90 |
| National Cancer Center, Japan | Phase 2 | Ovarian Clear Cell Carcinoma | 32 |
| Fudan University | Phase 2 | Gastric Adenocarcinoma; Gastroesophageal Junction (GEJ) Adenocarcinoma | 62 |
| Olivia Newton-John Cancer Research Institute | Phase 2 | Peripheral T-Cell Lymphoma Refractory | 25 |
All ClinicalTrialStartPulse record reports